(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
(19) World Intellectual Property Organization
(11) International Application
(43) International Publication Date
11 February 2016 (11.02.2016)
WO 2016/020544 Al

(51) International Patent Classification:
A61K 38/00 (2006.01)
A61P 33/02 (2006.01)
A23L 1/30 (2006.01)
C07K 14/335 (2006.01)
A61K 38/16 (2006.01)
C12N 15/74 (2006.01)
A61K 38/46 (2006.01)
A61K 35/714 (2015.01)
A61K 35/744 (2015.01)

(21) International Application Number:
PCT/EP2015/068334

(22) International Filing Date:
10 August 2015 (10.08.2015)

(25) Filing Language:
English

(26) Publication Language:
English

(30) Priority Data:
14306265.1 8 August 2014 (08.08.2014) EP


(74) Agent: REGIMBEAU; 20, rue de Chazelles, 75847 Paris Cedex 17 (FR).


Published:
— with international search report (Art. 21(3))
— with (an) indication* in relation to deposited biological material furnished under Rule 13bis separately from the description (Rule 13bis.4(d)(i) and 48.2(r)(viii))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS FOR THE INHIBITION OF GIARDIA LAMBLIA

(57) Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile- salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.
COMPOSITIONS FOR THE INHIBITION OF GIARDIA LAMBLIA

The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

Giardia lamblia is a parasitic protozoan responsible for giardiasis, a disease characterized by acute or chronic intestinal malabsorption, diarrhea, weight loss, dehydration and abdominal pain in humans and a variety of animals. It is one of the most common intestinal parasites in the world. Giardiasis has high veterinary impact and high impact on public health, is responsible for important human morbidity, especially causing nutritional deficiencies in children in developing countries (Ali and Hill, 2003). Developed countries are also concerned by giardiasis and outbreaks have been associated with drinking water contamination resulting from runoff of contaminated soils by rain falls, agricultural practices and sewage treatment plant dysfunctions (Mons et al., 2009).

G. lamblia enters vertebrates when cysts are ingested with food, water or fomites contaminated by feces from infected hosts. Cysts remain infective for months in environmental waters. They are highly resistant to chlorinated disinfectants used in drinking water treatments and infectious doses are low (10 to 100 cysts). After ingestion, infective forms excyst, releasing trophozoites that establish infections in the upper small intestine (duodenum) where they interact with the intestinal barrier. Duodenum is a very specific environment where food from the stomach, bile from the gall bladder and digestive enzymes from the pancreas pour in. There, G. lamblia divides by binary fission and eventually exits the host with the feces once trophozoites have re-formed cysts. The drug of choice for treating giardiasis remains metronidazole, a 5-nitroimidazole, which is reduced into toxic compounds by the parasite enzyme pyruvate:ferredoxin oxido-reductase. Side effects of drug treatment are reported and metronidazole resistance appears in vitro and in clinical settings (up to 20% of environmental strains were reported as resistant) (Upcroft and Upcroft, 2001).

How Giardia pathology is produced is still unclear but it is probably multifactorial (Farthing et al., 1997). Patho-physiologies observed comprise damages of the host mucosal surface by microvillus and crypt atrophy, decreased epithelial permeability and impairment of
the activity of digestive enzymes. These changes may be due as much to factors of the host as to those of the parasite.

It is now widely recognized that intestine microbiota plays a role in the protection of the host against gut colonization by pathogens (Travers et al., 2011). Different mechanisms may be responsible for the protective effects: competition for pathogen receptor sites, barrier for pathogen access, production of antimicrobial compounds, competition for nutritional substrates and enhancement of the innate and adaptive host immune responses (Tancrede et al., 1992). Nutritional strategies are based on an increase of the components of the gut microbiota that are associated with the protective activity (Brassard D. and Schiffrin EJ., 1997). Colonization of the intestine by G. lamblia strongly depends on the gut microbiota (Singer and Nash, 2000). Evidences strongly suggest the involvement of the bacterium Enterococcus faecium in the host immune response against G. lamblia (Benyacoub et al., 2005). Extracellular factors of L. johnsonii Lai block the in vitro growth of G lamblia in G1 phase indicating that bacteria may directly affect parasite development (Perez et al., 2001). It was shown that the probiotic bacteria Lactobacillus johnsonii Lai antagonizes G. lamblia establishment in rodent model (Humen et al, 2005).

The increasing numbers of outbreaks of giardiasis due to drinking water contamination, the side effects of available anti-Giardia drugs as well as, the increasing emergence of resistance to these drugs, render giardiasis a worrying subject, and there is a real need for alternative therapeutic strategies.

The present invention now provides compositions exhibiting a bile-salt hydrolase (BSH) activity as effective inhibitors for Giardia lamblia, for the prevention or the treatment of giardiasis. The inventors have indeed shown that parasite growth inhibition is mediated by secreted bacteria bile-salt hydrolase activity(ies) that produce(s) deconjugated bile salts from bile present in the culture medium, and that, unlike normal conjugated bile salts which are the main components of the bile, deconjugated bile salts are found toxic for Giardia.

reference number 1-2332), of Bifidobacterium bifidum (1-2333) or of Bifidobacterium infantis (1-2334). The inhibitory effect of lactic acid bacteria is possibly attributed to particular organic acids secreted by said lactic acid bacteria.

However, none of these documents disclose the role of bile-salt hydrolase activity, in the presence of bile salts, for the inhibition of Giardia lamblia.

A composition according to the present invention represents a new therapeutic strategy against Giardia lamblia, based on the natural catalytic activity of bile-salt hydrolases, in order to prevent or treat giardiasis. A composition according to the invention furthermore represents a public health interest by providing a means to counteract the emergence of drug resistant Giardia strains.

The invention will become more fully understood from the detailed description given herein and from the accompanying drawings, which are given by way of illustration only and do not limit the intended scope of the invention.

The present invention first relates to a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis.

The term "bile-salt hydrolase activity" or "BSH activity" refers to the ability of a composition according to the invention to hydrolyse conjugated bile-salts to generate deconjugated bile salts, and glycine or taurine. BSH cleave the peptide linkage of bile acids, which results in removal of the amino acid group from the steroid core and in the production of deconjugated, or unconjugated, bile acids, which precipitate at low pH.

The expression "treatment or prevention of giardiasis" refers to the treatment or the prevention of disorders associated with the presence in the gut of Giardia lamblia or of Giardia intestinalis, and in particular disorders associated with the infestation and/or colonization of the gut by said parasites.

Conjugated bile salts, or bile acids, are glycocholic acid (GCA), taurocholic acid (TCA), glycodeoxycholic acid (GDCA), taurodeoxycholic acid (TDCA), glycochenodeoxycholic acid (GCDCA) and taurochenodeoxycholic acid (TCDDA). Unconjugated bile-salts, also called deconjugated bile salts are: cholic acid (CA), deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA).

BSH activity is assessed by the detection the products generated by the enzymatic reaction, in particular the detection:

- of glycine and/or taurine, liberated from conjugated bile salts,
- of cholic acid (CA), deoxycholic acid (DCA) and/or chenodeoxycholic acid (CDCA)
by classical detection methods well known by a person skilled in the art of enzymology, including, without restriction, chromatography, mass-spectrometry, proteomic analysis, spectrophotometry, fluorometry, colorimetry or chemiluminescence, and any method such as described in the present specification. In a particular embodiment, CA, DCA and/or CDCA are detected by mass spectrometry analysis (LC/ESI-MS analysis) of bile components, and proteomic analysis.

A specific method for detection of BSH activity includes a method such as described in the present specification, using mass spectrometry analysis (LC/ESI-MS analysis) and proteomic analysis of bile components. It may also be detected, in bacteria, by a method comprising the growth of said bacteria in an adapted broth, the streaking of bacteria onto medium supplemented, or not, with 0.2% (wt/vol) glycodeoxycholic acid and anaerobic incubation for 48 h. The white precipitates around colonies and the clearing of the medium are indicative of BSH activity.

Therefore, the present invention relates to a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, said composition comprising at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus LalO* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),
- A recombinant host cell able to secrete at least one BSH.

The present invention also relates to a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, said composition comprising at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),
- A recombinant host cell able to secrete at least one BSH,

wherein said BSH activity is determined by the detection of the presence of glycine or taurine, liberated from conjugated bile salts, or by the detection of the presence of cholic acid (CA), deoxycholic acid (DCA), and/or chenodeoxycholic acid (CDCA).
The BSH activity of a BSH enzyme is expressed as enzymatic units (U) when tested using a taurodeoxycholic and/or a glycodeoxycholic substrate. An example of this determination is described in Example 13 of the present patent application. The level of the activity of a BSH, in a composition according to the invention, can be expressed by reference to the activity of commercial C. perfringens BSH, and possibly using a test for said activity as described in the C. perfringens manufacturer’s notice.

In a particular embodiment, the present invention relates to a composition exhibiting a BSH activity for use for the treatment or prevention of giardiasis, wherein said BSH activity is comprised between 0,0001 U and 100 U, between 0,001 U and 10 U, between 0,01 U and 1 U, between 0,1 U and 0,5 U.

In a first particular embodiment, the present invention relates to a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, wherein the bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.

In another particular embodiment, the present invention relates to a composition exhibiting a BSH activity for use for the treatment or prevention of giardiasis, wherein said composition comprises a BSH enzyme, or is a able to secrete at least one BSH enzyme, wherein the concentration of BSH present in said composition is comprised between 0,01 µg/ml and 10 mg/ml, between 0,1 µg/ml and 1 mg/ml, between 0,5 µg/ml and 200 µg/ml, between 1 µg/ml and 100 µg/ml, between 1 µg/ml and 50 µg/ml or between 5 µg/ml and 20 µg/ml. In a more particular embodiment, a composition according to the invention exhibits a bile-salt hydrolase activity associated with the presence of at least one bile-salt hydrolase (BSH) enzyme, said enzyme being chosen among prokaryotic BSH, or BSH synthesized by bacteria. In a more particular embodiment, a composition according to the invention exhibits a bile-salt hydrolase activity associated with the presence of at least one bile-salt hydrolase (BSH) enzyme synthetized by a lactic acid bacterium.

A lactic acid bacterium is defined as gram positive bacteria sharing common metabolic and physiological characters, wherein lactic acid is produced as a major metabolic end product of carbohydrate fermentation. The group of lactic acid bacteria includes in particular Lactobacillus, Lactococcus and Bifidobacterium. In a more particular embodiment, a composition according to the invention exhibits a bile-salt hydrolase activity associated with the presence of at least one bile-salt hydrolase (BSH) enzyme which amino acid sequence comprises an amino acid sequence having at least 80% identity, at least 85%, at least 90%, at
least 95%, at least 98% or at least 99% identity with, or which is a natural variant of, an amino acid sequence chosen in the group consisting of:

- **Lactobacillus johnsonii Lai** BSH-12 (LJ 1412) (SEQ ID No.1, UniProtKB entry number Q74IV4)
- **Lactobacillus johnsonii Lai** BSH-47 (LJ 1147) (SEQ ID No.2, UniProtKB entry number Q74JG0)
- **Lactobacillus johnsonii Lai** BSH-56 (LJ 0056) (SEQ ID No.3, UniProtKB entry number Q74LX7)
- **Lactobacillus gasseri** (ATCC reference: 33323) BSH-A (SEQ ID No.4, UniProtKB entry number B9V405)
- **Lactobacillus gasseri** BSH-B (SEQ ID No.5, UniProtKB entry number Q9AHJ7)
- **Lactobacillus johnsonii DPC 6026** (SEQ ID No.6, UniProtKB entry number F4AEI5),
- **Lactobacillus johnsonii DPC 6026** (SEQ ID No.7, UniProtKB entry number F4ACA3),
- **Lactobacillus johnsonii DPC 6026** (SEQ ID No.8, UniProtKB entry number F4ADE7).

Any BSH enzyme suitable in a composition according to the present invention is easily found by a man skilled in the art, and may be chosen, in particular, among the following:

- **Lactobacillus johnsonii DPC 6026 BSH**, UniProtKB entry number F4AEI5,
- **Lactobacillus johnsonii DPC 6026 BSH**, UniProtKB entry number F4ACA3,
- **Lactobacillus johnsonii DPC 6026 BSH**, UniProtKB entry number F4ADE7,
- **Lactobacillus johnsonii pfOl BSH**, UniProtKB entry number F7SHH3, and
- **Lactobacillus johnsonii pfOl BSH**, UniProtKB entry number F7SGA1.

The present invention comprises the presence of variants of BSH enzymes having at least 80%, at least 85%, preferably 90%, at least 90%, more preferably 95%, at least 95% and even more preferably 98%, at least 98% or at least 99% identity with a sequence chosen in the group consisting of SEQ ID No.1 to SEQ ID No.7. As used herein the term "identity" herein means that two amino acid sequences are identical (i.e. at the amino acid by amino acid) over the window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical amino acid residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e. the window size) and multiplying the result by 100 to yield the percentage of sequence identity. The percentage of sequence identity of an amino acid sequence can also be calculated using BLAST software with the default or user defined parameter. As applied to polypeptides, the term substantial identity means that two
peptide sequences, when optimally aligned, share at least about 80% sequence identity, preferably at least 85% identity, preferably at least about 90% sequence identity, more preferably at least about 95% sequence identity, at least 98% sequence identity or more (e.g., 99% sequence identity). As used herein, a "derivative" or "sequence derived from", or "natural variant" refers to an amino acid sequence having at least 80% identity, preferably at least 85% identity, more preferably at least 90% identity and even more preferably at least 95% identity or more, such as at least 98% sequence identity or 99% identity with said reference amino acid sequence.

More particularly, the present invention refers to a composition exhibiting a bile-salt hydrolase activity associated with a BSH enzyme, for its use in the prevention of the treatment of giardiasis, wherein the amino acid sequence of said enzyme is chosen among the following:

- *Lactobacillus johnsonii* Lai BSH-12 (SEQ ID N°1),
- *Lactobacillus johnsonii* Lai BSH-47 (SEQ ID N°2),
- *Lactobacillus johnsonii* Lai BSH-56 (SEQ ID N°3),
- *Lactobacillus gasseri* BSH-A (SEQ ID N°4),
- *Lactobacillus gasseri* BSH-B (SEQ ID N°5),
- *Lactobacillus johnsonii* DPC 6026 BSH (SEQ ID N°6), UniProtKB entry number F4AEI5,
- *Lactobacillus johnsonii* DPC 6026 BSH (SEQ ID N°7), UniProtKB entry number F4ACA3,
- *Lactobacillus johnsonii* DPC 6026 BSH (SEQ ID N°8), UniProtKB entry number F4ADE7.

In another particular embodiment, the invention relates to a composition exhibiting a bile-salt hydrolase activity for its use in the prevention of the treatment of giardiasis, wherein said composition comprises a lactic acid bacteria able to secrete a BSH, said lactic acid bacteria being chosen among: *Lactococcus*, *Lactobacillus*, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (NCC533, CNCM 1-1225) and of *Lactobacillus acidophilus* (NCC90, CNCM 1-2332), and *Bifidobacterium*, with the exception of the bacterial strains *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and of *Bifidobacterium infantis* (NCC200, CNCM 1-2334).

The term "lactic acid bacteria" refers to the presence of at least one micro-organism, wherein the micro-organism is preferably present of about 106 to 1012 cfu (colony forming unit). The microorganisms may be present as such or optionally after a step of purification from a culture medium. In another embodiment, a composition according to the invention comprises
the supernatant of a culture medium of said microorganism, which may be concentrated by any method known by a man skilled in the art.

Therefore, the invention relates to a composition exhibiting a bile-salt hydrolase activity for its use in the prevention of the treatment of giardiasis, said composition comprising a *Lactobacillus*, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (NCC533, CNCM 1-1225) and of *Lactobacillus acidophilus* (NCC90, CNCM 1-2332).

The invention also relates to a composition exhibiting a bile-salt hydrolase activity for its use in the prevention of the treatment of giardiasis, said composition comprising a *Bifidobacterium*, with the exception of the bacterial strains *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and of *Bifidobacterium infantis* (NCC200, CNCM 1-2334).

In a more particular aspect, a composition according to the invention comprises a *Lactobacillus* chosen in the group consisting of:

- *Lactobacillus johnsonii*, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (NCC533, CNCM 1-1225)
- *Lactobacillus gasseri*,
- *Lactobacillus acidophilus*, with the exception of *Lactobacillus acidophilus* (NCC90, CNCM 1-2332), and
- *Lactobacillus reuteri*.

The following bacterial strains have shown a particular activity in a composition according to the invention, as shown in the "Examples" part of the specification.

In a particular embodiment, the invention relates to a composition exhibiting a bile-salt hydrolase activity for its use in the prevention of the treatment of giardiasis, said composition comprising a lactobacillus chosen in the group consisting of the bacterial strains referenced as:

- *Lactobacillus johnsonii*:
  - Bacterial strain deposited at the CNCM, Institut Pasteur, Paris, under the number 1-4885, on August 7th, 2014
  - Bacterial strain deposited under the reference CIP103614,
  - Bacterial strain deposited under the reference CIP 103786,
  - Bacterial strain deposited under the reference CIP 103620,

- Bacterial strain deposited under the reference CIP103652,
- Bacterial strain deposited under the reference CIP103653,
- Bacterial strain deposited under the reference CIP103654,
- Bacterial strain deposited under the reference CIP103781,
- Bacterial strain deposited under the reference CIP103782,
- *Lactobacillus gasseri*:
  Bacterial strain deposited under the reference ATCC33353,
  Bacterial strain deposited at the CNCM, Institut Pasteur, Paris, under the number 1-4884, on August 7th, 2014,
  Bacterial strain deposited under the reference LMG1 1413.

- *Lactobacillus acidophilus*
  Bacterial strain deposited under the reference ATCC700396.

In a particular embodiment, the present invention relates to a composition exhibiting a BSH activity for the prevention or the treatment of giardiasis, said composition comprising a lactic acid bacteria able to secrete a BSH, wherein said bacteria are present in an amount comprised between $10^6$ to $10^{12}$ cfu/g of bacteria.

In another particular embodiment, the present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use in the prevention of the treatment of giardiasis, said composition comprising a host cell comprising a heterologous nucleic acid sequence encoding for at least one bile-salt hydrolase enzyme, said host cell being able to secrete said bile-salt hydrolase enzyme.

The term "host cell" refers to a living cell able to receive heterologous nucleic acid, and able to synthesize at least one protein encoded by said heterologous nucleic acid. In a preferred embodiment, said heterologous nucleic acid is an expression vector containing nucleic acid sequences able to encode a protein of interest and all necessary regulatory elements for the production of said protein in said host cell.

In a more particular embodiment, a composition according to the invention comprises a host cell comprising at least one nucleic acid sequence chosen among the following:

- nucleotide sequence encoding for *L. johnsonii Lai BSH-12* (SEQ ID No9), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID No9,
- nucleotide sequence encoding for *L. johnsonii Lai BSH-47* (SEQ ID No10), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID No10,
- nucleotide sequence encoding for *L. johnsonii Lai BSH-56* (SEQ ID No1 1), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%,
at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID N°II.

In another particular embodiment, the invention relates to a host cell for use in the treatment or the prevention of giardiasis, said host cell comprising at least one nucleic acid sequence, wherein said at least one nucleic acid sequence may be heterologous, chosen among the following:

- nucleotide sequence encoding for *L. johnsonii* Lai *BSH*-12 (SEQ ID N°9), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%>, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID N°9,

- nucleotide sequence encoding for *L. johnsonii* Lai *BSH*-47 (SEQ ID N°10), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%>, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID N°10,

- nucleotide sequence encoding for *L. johnsonii* Lai *BSH*-56 (SEQ ID N°11), or a natural variant thereof, wherein said natural variant has a nucleotide sequence of at least 80%>, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% identity with SEQ ID N°11.

Any BSH enzyme suitable in a composition according to the present invention can be selected by a man skilled in the art, and a nucleotide sequence encoding for said enzyme can be found in public databases, it may be chosen, in particular, among the following:

- *Lactobacillus johnsonii* DPC 6026 *BSH*, UniProtKB entry number F4AEI5,
- *Lactobacillus johnsonii* DPC 6026 *BSH*, UniProtKB entry number F4ACA3,
- *Lactobacillus johnsonii* DPC 6026 *BSH*, UniProtKB entry number F4ADE7,
- *Lactobacillus johnsonii* pj 01 *BSH*, UniProtKB entry number F7SHH3,
- *Lactobacillus johnsonii* pf01 *BSH*, UniProtKB entry number F7SGA1,
- *Clostridium perfringens* BSH
- *Lactobacillus acidophilus* BSH, bacterial strain referenced as ATCC700396.

In a more particular embodiment, a composition according to the present invention comprises a host cell comprising at least one nucleic acid sequence encoding for a BSH, said host cell being chosen in the group of lactic acid bacteria. More particularly, said lactic acid bacterium is chosen among lactobacilli and lactococci. In a particular embodiment of the invention, said lactic acid bacterium is *Lactococcus lactis*. In another particular embodiment of the invention, said lactic acid bacterium is a lactobacilli chosen among the group consisting of:
- *Lactobacillus johnsonii*,
- *Lactobacillus reuteri*, and
- *L Lactobacillus gasseri*.

In another aspect, the present invention relates to the use of a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, wherein said composition comprises:

- A bile-salt hydrolase (BSH) enzyme,
- A bacteria able to secrete at least one BSH, with the exception of the strain *Lactobacillus johnsonii* Lai, *Lactobacillus acidophilus, Bifidobacterium bifidum* and *Bifidobacterium infantis*,
- A recombinant host cell able to secrete at least one heterologous BSH, or
- A combination thereof.

In a more particular embodiment, the present invention relates to the use of a composition exhibiting a bile-salt hydrolase activity wherein said composition comprises: a bile-salt hydrolase (BSH) enzyme, a bacteria able to secrete at least one BSH, with the exception of the strain *Lactobacillus johnsonii* Lai, *Lactobacillus acidophilus, Bifidobacterium bifidum* and *Bifidobacterium infantis*, a recombinant host cell able to secrete at least one heterologous BSH, or a combination thereof for the treatment or the prevention of giardiasis, in human beings.  

In another more particular embodiment, the present invention relates to the use of a composition exhibiting a bile-salt hydrolase activity wherein said composition comprises: a bile-salt hydrolase (BSH) enzyme, a bacteria able to secrete at least one BSH, with the exception of the strain *Lactobacillus johnsonii* Lai, a recombinant host cell able to secrete at least one heterologous BSH, or a combination thereof for the treatment or the prevention of giardiasis in animals. Indeed, a composition according to the invention may be used for the treatment or the prevention of giardiasis in pigs and in cows, therefore, in a particular embodiment, a composition according to the invention is for use in the treatment or prevention of giardiasis in pigs or in cows.

In a further aspect, the present invention relates to a pharmaceutical composition comprising, as an active principle, a BSH, a lactic acid bacteria able to secrete at least a BSH, a host cell able to secrete a BSH, or a combination thereof, and a pharmaceutically acceptable carrier.

A pharmaceutical composition according to the invention comprises an effective amount of a BSH, a lactic acid bacteria able to secrete at least a BSH, a host cell able to secrete a BSH, or a combination thereof, and a pharmaceutically acceptable carrier, wherein said
effective amount is defined as catalytic units (U), for BSH enzyme or recombinant BSH enzyme, or as a number of colony forming units (cfu), for living bacteria.

A pharmaceutical composition according to the invention is selected from an orally administrable composition, including, with no restriction, tablets, liquid bacterial suspension, dried oral supplement, wet oral supplement and tube feeding compositions.

Other pharmaceutical or nutritional preparations suitable for oral administration are hard or soft gelatin capsules made from gelatin and a plasticizer such as glycerol or sorbitol. Hard capsules may include the inventive compound in admixture with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate, and if desired, stabilizers.

In soft capsules, the inventive compound is preferably dissolved or suspended in a suitable liquid, such as fatty oil, paraffin oil or a liquid polyethylene glycol, to which a stabilizer can be added.

In a particular embodiment, a pharmaceutical composition according to the invention comprises an effective amount of a BSH enzyme and a pharmaceutically acceptable carrier for an administration to animals. In a more particular embodiment, a pharmaceutical composition from the invention comprises a BSH-12, a BSH-47 and/or a BSH-56 enzyme, and a carrier comprising a vehicle for oral administration of molecules, mixed with a cell culture buffer.

A person skilled in the art is able to choose an adapted vehicle, as an example, the SYRSPEND® can be cited, and to prepare and adapted mixture for its oral administration, for example by mixing said vehicle with a diluting solution and/or with a buffer. As an example, a pharmaceutical composition according to the invention comprises an effective amount of BSH-12, a BSH-47 and/or a BSH-56 enzyme and a carrier comprising a mixture of SYRSPEND® NaHC03 16.4%, DMEM (Dilbecco Modified Culture Medium).

Coated tablet cores can be provided with suitable coatings, which if appropriate are resistant to gastric juices, using, inter alia, concentrated sugar solutions which may contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, shellac solutions in suitable organic solvents or solvent mixtures or, for the preparation of coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylated cellulose phthalate or hydroxypropylmethylcellulose phthalate. Dyes or pigments can be added to the tablets or coated tablets, for example, to identify or indicate different doses of the active compound ingredient.

In a more particular embodiment, the present invention relates to a pharmaceutical composition comprising a BSH, a lactic acid bacterium able to secrete at least a BSH, a host cell able to secrete a BSH, or a combination thereof as an active principle, wherein said active principle is encapsulated.
In another particular embodiment, the present invention relates to a process for the preparation of a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, said composition comprising a carrier and at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii Lai* (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus LalO* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),

In a more particular embodiment, the present invention relates to a process for the preparation of a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, said composition comprising a pharmaceutically acceptable carrier and at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii Lai* (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus LalO* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),

In another more particular embodiment, the present invention relates to a process for the preparation of a composition exhibiting a bile-salt hydrolase activity for the treatment or the prevention of giardiasis, said composition comprising a carrier acceptable for a food composition or a dietary supplement and at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii Lai* (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus LalO* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),

A process according to the invention comprises at least a step of contacting said carrier with an effective amount of said enzyme and/or said bacterium and/or said host/cell, wherein
said and a step of mixing said elements in order to prepare a composition suitable for its intended use.

The present invention also relates to a method for the prevention or for the treatment of giardiasis, said method comprising the administration, to a patient in need thereof, of a composition comprising at least one of the following elements, or a combination thereof:

- A bile-salt hydrolase (BSH) enzyme,
- A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii* Lai (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),
- A recombinant host cell able to secrete at least one BSH,

In a further aspect, the present invention relates to a food composition or a dietary supplement comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete at least a BSH, a host cell able to secrete a BSH, or a combination thereof, and optionally a carrier.

A food composition or a dietary supplement according to the invention comprise an effective amount of a BSH, a lactic acid bacteria able to secrete at least a BSH, a host cell able to secrete a BSH, or a combination thereof, and a pharmaceutically acceptable carrier, wherein said effective amount is defined as catalytic units (U), for BSH enzyme or recombinant BSH enzyme, or as a number of colony forming units (cfu), for living bacteria.

A food composition or a dietary supplement according to the invention may be provided as a dry or a wet composition, and may be selected, with no restriction, among milk, yogurt, cheese, milk powder and pet food.

**LEGENDS OF THE FIGURES**

**Figures 1A and 1B:** inhibitory effect of LjLal supernatant on *G. lamblia*. Fig. 1A represents parasites concentration as a function of incubation time in the presence of KM-FCS with (filled symbols) or without (open symbols) bovine bile (0.75 g/L, final concentration), in presence (squares) or absence (diamonds) of bacterial supernatant (LjLalsn). The parasite concentration was estimated by counting lived cells with a Malassez cell chamber, as indicated in example 1. N=2. Fig. 1B represents the percentage of *G. lamblia* growth inhibition after 24h of culture is expressed as a function of bile salts concentration (grey histograms) or of complete bovine bile (black histograms, right part of the figure). *G. lamblia* trophozoites in KM-FCS were incubated for 24h at 37°C in anaerobic conditions with LjLalsn and various concentrations of bile salts (0.016, 0.032, 0.048 g/L, final concentration) or complete bovine bile (0.5, 0.6, 0.75 g/L, final
concentration). Growth inhibition values (%) were normalized according to control in lactic acid-acidified KM-FCS supplemented with similar concentrations of bovine bile or bile salts. Number of independent experiments = 3.

**Figures 2A to 2C:** percentage of *G. lamblia* growth inhibition after 24h of culture. Fig. 2A represents the percentage of *G. lamblia* in the presence of (from left to right) LjLalsn with no protease treatment, LjLalsn with proteinase K, LjLalsn with pronase; LjLalsn with catalase or heated at 90°C for 10 min before *G. lamblia* growth inhibition assay. Growth inhibition (%) was normalized according to control: lactic acid-adjusted MTYI medium incubated with protease-coupled beads or treated for 10 min at 90°C. Number of independent experiments = 3. Figure 2B represents the percentage of *G. lamblia* growth inhibition after 24h of culture in varying pH. Supernatant from LjLal in MTYI medium was adjusted to pH 6.2, 6.7, 6.9 or 7.2 (histograms from left to right) before *Giardia* growth inhibition assays. Growth inhibition (%) was normalized according to control, i.e. lactic acid-adjusted MTYI subsequently raised to pH 6.2, 6.7, 6.9 or 7.2. Number of independent experiments = 3. Figure 2C represents the percentage of *G. lamblia* growth inhibition after 24h of culture in supernatant from a culture of LjLal in KM-FCS medium filtered through a 10 kDa, 30 kDa or 50 kDa MW cut-off membrane (from left to right). Acidified KM-FCS alone was processed similarly. Fractions above and under respective thresholds were assayed for *Giardia* growth inhibition in presence of bile (0.5 g/L). Inhibition values (%) were normalized according to KM-FCS controls. Number of independent experiments = 3.

**Figures 3A to 3C:** impact of LjLal supernatant on bovine bile composition, as shown by total ion chromatograms detected by LC-MS of the SPE-treated samples corresponding to an incubation of the bile for 24h at 37°C with either KM medium alone (Figure 3A), LjLal supernatant (Figure 3B) or heat-treated LjLal supernatant (Figure 3C). Metabolic profiles were established, from which the main components were identified using Metlin (Smith et al., 2006) or LMSD (Sud et al., 2007) databases, or from their MS/MS fragmentation pattern. TC: taurocholate, GC glycocholate, TCDC: taurochenodesoxycholate, TDC: taurodesoxycholate, GCDC: glycochenodesoxycholate, GDC: glycodesoxycholate, C: cholate, CDC: chenodesoxycholate, DC: desoxycholate.

**Figures 4A and 4B:** Increase of non-conjugated salts cholate and deoxycholate content after treatment of bile with LjLal supernatant. Figures 4A and 4B represent boxplot showing the relative intensity of cholate (C) and deoxycholate (DC) for the bile incubated in the absence (left) presence (right) of LjLal supernatant.
Figures 5A to 5C: *G. lamblia* growth inhibitory activity and BSH activity co-eluate in the same fractions after separation of LjLal supernatant by gel filtration chromatography. Figure 5A: Chromatography profile. Figure 5B: BSH activity measured after 24h of incubation of GDC (2.4 g/l) with gel filtration fraction collected. Figure 5C: *G. lamblia* growth inhibitory activity after 24h of incubation with gel filtration chromatography fractions in presence of GDC (0.2 g/l).

Figure 6: Inhibition of *Giardia lamblia* growth by enzymatically active *C. perfringens* BSH in the presence of glycine- (GDC, GCDC) or taurine- (TDC, TCDC) conjugated bile salts. Commercial *C. perfringens* BSH, enzymatically active (dark bars) or inactivated (light bars) by a heat-treatment (100°C, 5 min) was added to *G. lamblia* growth medium. GDC: glycodeoxycholate, GCDC: glycochenodesoxycholate, TDC: taurodesoxycholate, TCDC: taurochenodesoxycholate.

Figures 7A to 7D: Measurement of *G. lamblia* inhibition by flow cytometry.

Figure 8: Percentage of living *G. lamblia* parasites when cultivated in the presence of varying *Lactobacillus* strains.

Figure 9: Enzymatic activity of recombinant BSH-47 produced in *E. coli*. *E. coli* wild type or *E. coli* secreting BSH-47 were incubated in the presence of taurodeoxycholic acid 0.3% (upper panels) or in the presence of glycodeoxycholic acid 0.3% (lower panels).

Figure 10: Histogram representing the number of living *Giardia* parasites (in cells per ml) after incubation with (from left to right) medium, medium and bile, *C. perfringens* BSH (1U), *C. perfringens* and bile, recombinant BSH-47, recombinant BSH-47 and bile.

Figures 11A and 11B: Inhibition of *Giardia lamblia* growth by enzymatically active recombinant BSH from LjLAI in the presence of bovine bile (0.6g/L) after 20h of incubation. Figure 11A represents the inhibition of *G. lamblia* growth by recombinant BSH-47. Figure 11B represents the inhibition of *G. lamblia* growth by recombinant BSH-56.

Figures 12A and 12B: *G. lamblia* cysts or trophozoites counts after administration to animals. Newborn mice received either PBS, LjLal or *L. gasseri* CNCM 1-4884 by intragastric gavage (5. 10^8 CFU/mice) daily from day 5 before inoculation with the trophozoites of *G. lamblia* WB clone C6 (10^5 trophozoites per animal). Gavages were performed until day 15 (n=8 to 12/group). Figure 12A: Giardia trophozoites count in the small intestine. Values are mean ± SEM; p < 0.05. Figure 12B: Giardia cysts counts in large intestine of mice belonging to different groups. Values are mean ± SEM; p <0.05.

Figure 13: *G. lamblia* trophozoites count in the small intestine. Mice were challenged with the trophozoites of *G. lamblia* WB clone C6 (10^5 trophozoites per animal) at day 10. Animals were
treated either with PBS or BSH-47 at 1µg/mi (O^g per mice), 1C^g/ml (5µg per mice) or 10C^g/ml (50µg/mice) by daily intragastric gavage until day 15 (n=10 to 11/group). Values are mean ± SEM ;p <0.05.

EXAMPLES

Example 1: Material and methods

Products and preparation of stock solutions

Bovine bile solutions (Sigma and Difco) were prepared at 100 mg/ml stock solution in distilled water, filtered at 0.2 µm and stored at -20°C. Pure bile salts (Sigma): glycocholate (GC), taurocholate (TC), glycodeoxycholate (GDC), taurodeoxycholate (TDC), glycochenodeoxycholate (GCDC) and taurochenodeoxycholate (TCDC), bile salt mix (Sigma) or pure corresponding bile salts (Sigma): cholate (C), deoxycholate (DC) and chenodeoxycholate (CDC), and fusidic acid (Sigma) were dissolved in distilled water to 12 mg/ml stock solution, filtered at 0.2 µm and kept at -20 °C. Choloylglycine Bile Acid Hydrolase (or Bile Salt Hydrolase, BSH, EC 3.5.1.24) from Clostridium perfringens (Sigma) was prepared at 10 U/ml in distilled water (milli-Q grade) and stored at -20 °C. Iodoacetic acid (Sigma) was prepared as 0.5 M stock solution in distilled water and frozen at -20 °C. Fetal calf serum was from PAA Laboratories, GE Healthcare. The NEFA-C kit used for quantitative determination of non-esterified fatty acids (NEFAs) was from Biolabo (WAKO Diagnostics).

Cell culture of Giardia lamblia

Trophozoites of G lamblia strains WB (clone C6, ATCC30957) and HP1 (Portland-1., gift of J. Tackezy) were grown as previously described in TYI-S-33 Keiser's medium (KM) with some modifications. TYI-S-33 was adjusted at pH 6.0, supplemented with 10% heat-inactivated fetal calf serum (Paget et al., 2004) and 0.6 mg/ml bovine bile (Carnaby et al., 1994). They were regularly subcultured at a density of 5 x 10^4 cells per tube (12 ml) from log phase parasites chilled on ice for 10 min and centrifuged at 700 x g, 5 min.

Culture of Lactobacillus johnsonii and production of bacterial supernatant

L. johnsonii Lai (LjLal), CNRZ 1897, NCC533, was kindly provided by Pascal Quenee (INRA Jouy en Josas, Equipe Atalis) and has been isolated from LCI product in 1996 (Chambourcy, France). LjLal stock cultures were kept frozen in MRS Broth media with 15% glycerol. Bacteria were subcultured in MRS Broth medium (Sigma) or modified TYI-S-33 medium (MTYI) (Perez et al. 2001) and incubated anaerobically for 12-18 h at 37 °C. Bacteria were
subsequently grown in MTYI or KM medium supplemented or not with 10% heat-inactivated fetal calf serum for 12-16 h in the presence or absence of 0.6 mg/ml bovine bile. After centrifugation (3,000 x g, 10 min) and 0.2 µm filtration, the pH of the bacterial supernatant was adjusted to 6.0, 6.2, 6.7, 6.9 or 7.2 with 5 N NaOH. Appropriated controls were prepared as follows: lactic acid produced during growth was quantified from aliquots of supernatants (Enzytec™ kit, R-Biopharm) and equivalent amount of lactic acid was added to fresh medium before pH adjustment.

**In vitro G. lamblia growth inhibition assay**

One milliliter of trophozoites suspension (1 x 10^5 parasites/ml in KM supplemented with 10% fetal calf serum but without bovine bile) was mixed with either 500 µl of bacterial supernatant or bile salt hydrolase from *Cperfringens* (BSH, 0.2, 1 or 2 U) or appropriate controls in KM or MTYI, in the presence of different concentrations of either bovine bile (0 to 0.6 mg/ml), mixed bile salts (0 to 0.2 mg/ml), conjugated bile salts (0 to 0.2 mg/ml) or deconjugated bile salts (0 to 0.2 mg/ml). Samples were incubated for 24 h at 37 °C and then chilled on ice for 10 min to dislodge trophozoites from tube wall. Living trophozoites (parasites with pear shape showing signs of flagella mobility) were counted using Malassez cell chamber and/or using an hemocytometer. Multiplication factor (i.e. number of total trophozoites at the end of the experiment / number of trophozoites at time zero), survival rate (i.e. (number of living cells / total number of trophozoites) x 100) and inhibition percentage (i.e., 100-(number of living cells in the presence of tested compounds/ number of living cells in control) x100) were calculated.

**Partial purification of active fractions from bacterial supernatants by gel filtration**

Supernatants from LjLal cultures in MTYI or KM, adjusted to pH 6.0, were concentrated up to 30-fold by ultrafiltration using 10 kDa Centriprep centrifugal filter unit (Millipore). After 0.2 µm filtration, the concentrated supernatants were placed on a Sephacryl S300 column 16/100 (GE Healthcare) previously equilibrated with 20 mM ammonium sulfate, pH 6.0, in a cold room and were eluted with the same buffer at a flow rate of 1.8 to 2.0 ml/min. Twelve effluent fractions of 12 ml were obtained, concentrated 4-fold by ultrafiltration on a 10 kDa Centriprep as described above, and tested for *Giardia* inhibition by classical *in vitro* growth inhibition assays in the presence of bovine bile or bile salts. Fractions obtained by similar processing of elution buffer alone and control media containing lactic acid (see above) were used as controls. Column calibration was carried out with ribonuclease A (13,700 Da) and bovine serum albumin (67,000 Da).
Characterization of the active molecule(s) in LjLal supernatant

Molecular size of active molecule(s) present in the bacterial supernatant was assessed by ultrafiltration using 10 kDa, 30 kDa and 50 kDa Centriprep centrifugal filter units. Thermal stability was tested by heating bacterial supernatant at 90°C for 10 minutes. Preservation of the LjLal supernatant activity upon dialysis was checked by dialyzing twice (for 2 h and 15 h at 4°C, respectively) the supernatant against 100 volumes of KM medium supplemented with 10% FCS or against GKN solution (Perez et al., 2001) (NaCl, 8 g/l; KC1, 0.4 g/l; glucose, 2g/l; NaH2PO4·H2O, 0.69 g/l; Na2HP04·1.57 g/l; pH 7.2 to 7.4) using a MWCO 3.5 kDa Spectra-Por dialysis membrane. The dialyzed supernatant was then sterilized by filtration through 0.2 µm membrane and kept frozen at -80°C before G lamblia inhibition assays.

Finally, biochemical nature of active molecules was determined by preincubating 5-fold concentrated bacterial supernatant obtained by ultrafiltration (>10 kDa) with different proteases coupled to beads. Briefly, proteinase K (Invitrogen) and pronase (Merck) were coupled to CNBr-activated Sepharose™ 4B (GE Healthcare) following manufacturer’s instructions. Five milliliter of 5-fold concentrated bacterial supernatant or 5-fold concentrated fresh control medium were incubated for 6 h at room temperature in presence of 100 µl of packed beads previously coupled with 1 mg of each protease. Before growth inhibition assays, beads were removed by centrifugation (4,000 x g 5 min). To assess proteases ability to digest proteins from bacterial supernatant, protein content before and after incubation with proteases, was estimated by SDS-PAGE after trichloroacetic acid (TCA) precipitation.

Measurement of free fatty acids

To assess the presence of free fatty acids in the complex medium inducing Giardia growth inhibition, FCS, bile and LjLal supernatant (LjLal sn) were analyzed for non-esterified fatty acids (NEFAs) content either alone (FCS, LjLal sn, bile) or in combination (FCS-bile, FCS-LjLal sn, bile-LjLalsn, FCS-bile-LjLalsn). Concentration of each component was that in the inhibition assay. Samples (0.5 ml) were prepared and kept on ice before being incubated for 24 h at 37°C in the presence of 4.8 x 10^4 trophozoites or without cells. At the end of the incubation period, tubes were chilled on ice, centrifuged at 700 x g, 10 min at room temperature, then the supernatant was taken and frozen at -80°C before NEFAs measurement. Numbers of living and dead trophozoites were determined using a Malassez cell chamber. NEFAs were quantified by using the NEFA-C kit, following manufacturer’s instructions. Oleic acid was used as standard and NEFAs were expressed as oleic acid equivalents (Eq).
Bile salt hydrolase activity assays
After gel filtration, the eluted fractions were concentrated 10-fold by dialysis against 20mM ammonium acetate buffer containing 2 M sucrose, pH 6.0, using a 3.5 kDa MWCO membrane (Spectrum Laboratories). Glycodeoxycholate (GDC) was used to perform growth inhibition assays and enzymatic assays. BSH activity was monitored by measuring glycine liberation from conjugated bile salt, following the protocol described by Grill et al. (2000). Briefly 100 μl of effluent fractions or BSH 1 unit or elution buffer were mixed with 100 μl of 2.4 g/l of GDC and incubated 24h at 37°C. Controls were performed in the absence of bile salt or by pre-incubating effluent fractions with 2 mM iodoacetic acid or 30 min at 37°C. To stop the enzymatic reaction, an equal volume of 15 % TCA (200 μl) was added and proteins were precipitated by centrifugation at 20,000g for 15 minutes. 680 μl of 0.3M borate buffer, 1% SDS, pH 9.5 and 80 μl of 0.3% picrylsulfonic acid solution (Sigma) were added to 80 μl of supernatants. Mixtures were incubated for 30 min in the dark and 800 μl of 1 mM HCl were added to stop the reaction. Glycine concentration was measured at 416 nm using an Uvikon spectrophotometer 930 (Kontron Instruments). Standard curve was established with free glycine.

LC/ESI-MS analysis of modifications of bile components by LjLal supernatants
125 μl of bile-containing culture media of G. lamblia (KM, pH 6.0, with 2 g/L bovine bile) and 125 μl of LjLal supernatants prepared from a bacterial culture in KM medium supplemented with 10% fetal bovine serum, adjusted at pH 6.0 were mixed and incubated overnight at 37°C. Two different bile batches (B1 and B2) and two different bacterial supernatants (SI and S2) were tested. The samples were diluted 4-fold in Milli-Q water and subjected to solid-phase extraction (SPE) using Oasis® HLB cartridges (30 mg solid phase). After conditioning with 3 ml methanol and 3 ml Milli-Q water, the cartridges were loaded with 1 ml of 4-fold diluted sample, washed with 2 ml Milli-Q water and eluted with 2 ml methanol. The eluted fractions were dried under vacuum and resuspended in 500 μl Milli-Q water/acetonitrile 90: 10 (v/v). Five μl of each resuspended sample was analyzed by LC/ESI-MS on a Ultimate U3000 chromatographic system (Thermo) connected to a Q-STAR Pulsar Qq-TOF mass spectrometer equipped with an ionspray source (AB Sciex). The LC separation was achieved on an Interchrom Strategy C18-2 micro column (5 μm, 150 x 1 mm, 100 A, Interchim). The elution gradient was 10%, mobile phase B (acetonitrile) to 70% B against mobile phase A (5 mM ammonium formate/formic acid, pH 6) over 45 min, at a flow rate of 40 μl/min. The MS data were acquired in negative mode, in the range m/z 250-1200. Each LC/ESI-MS experiment was conducted twice. Data-dependant LC/ESI-MS/MS experiments were also conducted on each sample,
alternating 1-second full-scan MS followed by two 2-second product ion collision induced
dissociation (CID) of the major ions detected at the first step, using a -50 V collision voltage.
Each raw LC/ESI-MS data was converted into Network Commun Data Form (NetCDF) using
the translation tool provided by AB Sciex. The data were processed with XCMS (Smith et al.
2006), a software implemented in the freely available R environment (www.r-project.org),
which allows automatic retention time alignment, matched filtration, peak detection and peak
matching.

Protein precipitation
0.1% of sodium lauroyl sarcosinate (NLS, Sigma) was added to bacterial supernatants. After
mixing, TCA (trichloroacetic acid) was added to a final 7.5% concentration, and the solution
was precipitated on ice overnight. The mixed protein-detergent precipitate was collected by
centrifugation (10,000 x g, 10 min, 4°C). The supernatant was carefully removed and the pellet
washed twice with 2 ml of precooled tetrahydrofuran (Sigma). Finally, the pellet was dissolved
in 0.4 ml extraction solution (7 M Urea, 2 M Thiourea, 4% CHAPS, 5 mM
Tris(carboxyethyl)phosphine) (Rabilloud et al., 2009).

Proteomic analysis of LjLal supernatant
TCA precipitated LjLal supernatant was resuspended in 8 M urea in 20 mM TEAB
(triethylammonium bicarbonate) and incubated for 1 h at room temperature (RT) with 20 mM
DTT (Dithiothreitol), then with 50 mM IAA (iodacetamide) and incubated for a further hour at
RT in the dark. The sample was incubated with 0.05 UA of endoproteinase Lys-C (Wako Pure
Chemical Industries, Osaka, Japan) for 18 h at RT. Trypsin (Promega) digestion was performed
with 2 µg of enzyme during 4 h at RT and terminated with TFA (trifluoroacetic acid), final
concentration of 0.5%. The sample was passed sequentially through two home-made Poros
01igo-R3 (PerSeptive Biosystems, Framingham, USA) microcolumns packed (+1 cm) on p200
tips over 3MM C18 material plug. Loaded resin was washed with 100 µl 0.1% TFA and
peptides were eluted with 100 µl 70% acetonitrile (ACN)/ 0.1% TFA, then 20 µl 100% ACN.
The sample was desalted, dried down, resuspended in 50% ACN and 10% was collected to
amino acid analysis using a Biochrom 30 amino acid analyzer (Biochrom, Cambridge, U.K.),
then dried and stored at -80°C again until analysis.

Samples (3 µg per run) were analyzed by an EASY-nano LC system (Proxeon Biosystems,
Odense, Denmark) coupled online to an LTQ-Orbitrap Velos mass spectrometer (Thermo
Scientific, Waltham, USA). Peptides were loaded onto a 18 cm fused silica emitter 75 µm inner
diameter) packed in-house with reverse phase capillary column ReproSil-Pur C18-AQ 3 µm
resin (Dr. Maisch GmbH, Germany) and eluted using a gradient from 100%, phase A (0.1%
formic acid) to 35% phase B (0.1% formic acid, 95% acetonitrile) for 180 min, 35% to 100% phase B for 5 min and 100%, phase B for 8 min (a total of 23 min at 250 nl/min). After each run, the column was washed with 90% phase Band re-equilibrated with phase A. Mass spectra were acquired in positive mode applying data-dependent automatic survey MS scan and tandem mass spectra (MS/MS) acquisition. Each MS scan in the orbitrap (mass range of m/z of 400-1800 and resolution 100,000) was followed by MS/MS of the fifteen most intense ions in the LTQ. Fragmentation in the LTQ was performed by collision-induced dissociation and selected sequenced ions were dynamically excluded for 25 s. Raw data were viewed in Xcalibur v.2.1 (Thermo Scientific, Waltham, USA) and data processing was performed using Proteome Discoverer v.1.3 (Thermo Scientific, Waltham, USA). Generated raw files were submitted to searching using Proteome Discoverer with an in house Mascot v.2.3 algorithm against database of proteins predicted from the L. johnsonii isolates NCC533 and FI9785 and the L. johnsonii prophage Lj965. Contaminant proteins (several types of human keratins, BSA and porcine trypsin) were also added to the database and all contaminant proteins identified were manually removed from the result lists. The searches were performed with the following parameters: ms accuracy 10 ppm, MS/MS accuracy 0.6 Da, trypsin digestion with one missed cleavage allowed, fixed carbamidomethyl modification of cysteine and variable modification of oxidized methionine and N-terminal protein acetylation. Number of proteins, protein groups and number of peptides were filtered for False Discovery Rates (FDR) less than 1% and only peptides with rank 1 and minimal of 2 peptides per proteins were accepted for identification using Proteome Discoverer (Charneau et al., 2007; Queiroz et al. 2013).

Example 2: L. johnsonii Lai supernatant inhibitory effect is dependent upon bovine bile and more specifically upon bile salts

Most media previously described to support G. lamblia growth commonly contains bile as a supply for parasite cholesterol and fatty acids requirements (Farthing et al., 1985, Gillin et al., 1986, Halliday et al., 1995).

In our hands, G. lamblia trophozoites growth can be observed in a common medium (KM-FCS) in the absence of bovine bile. Moreover, recommended bile concentrations (0.75 mg/ml, Perez et al., 2001) appeared to affect trophozoites growth when added to the common KM-FCS (Figure 1A). Interestingly, LjLal inhibitory effect was observed only in presence of bile. No inhibitory effect by the supernatant could be observed in the absence of bovine bile, even after 24 h of culture (Figure 1A). In presence of 0.75 g/L of bovine bile (Perez et al., 2001), G. lamblia trophozoites growth was slightly impacted by bacterial supernatant after 10 hours of
contact but largely affected after 24 hours of contact (9.10^4 and 1.10^4 trophozoite/ml, respectively, Figure 1A). Thus, the 24h incubation time-period was retained for all subsequent inhibitory growth assays.

Maximum inhibitory effects of LjLal supernatant on parasite growth was observed either in the presence of 0.6 g/L complete bovine bile or in the presence of 0.032 g/L bile salts (96.3% and 75%, of inhibition, respectively, by comparison with controls containing similar amount of lactic acid and bile or bile salts, Figure IB). Similar effects were observed using two isolates of G. lamblia (WB and HP1), two different commercial origins of bovine bile and two different media compatible with bacteria and parasite growth: MTYI (Perez et al., 2001) and KM-10%> FCS (Data not shown). Subsequent inhibition in vitro assays were thus performed using 0.6 g/L of bovine bile.

**Example 3: Characterization of the inhibitory activity**

To biochemically characterize the inhibitory compounds present in the LjLal supernatant, this supernatant was treated with immobilized enzymes prior to contact with parasites. Parasite growth inhibition was abolished by proteinase K and pronase treatments of the supernatant, suggesting involvement of inhibitory factor(s) of peptidic nature (Figure 2A). Heat-treatment also led to inactivation of the inhibitory properties of the bacterial supernatant (Figure 2A). Additionally, in a pH range similar to the ones experienced by G. lamblia in vivo (Biagini et al., 2001), a strong influence of pH on the inhibitory reaction was noticed, with highest inhibition occurring at pH 6.2 (Figure 2B).

Moreover, as Pridmore et al. (2004) demonstrated that the LjLal anti-Salmonella activity is mediated by the toxic hydrogen peroxide molecule H_2O_2 and can be abolished by a pretreatment with catalase, we checked whether treatment of LjLal supernatant with catalase might prevent its anti-Giardia effect. As it can be seen in figure 2A, catalase pretreatment only slightly affected the inhibitory activity of the LjLal supernatant on G. lamblia (Figure 2A), invalidating the role of H_2O_2 in Giardia growth inhibition.

**Example 4: Giardia growth inhibition by LjLal supernatant is not due to free fatty acids**

To assess whether G. lamblia growth inhibition by LjLal supernatant might be due to toxic free fatty acids as demonstrated in previous reports (Rohrer et al. 1986), FCS, bile and LjLal supernatant were analyzed for non-esterified fatty acids (NEFAs) content either alone or in combination, using the NEFA-C methodology (WAKO diagnostics). The different samples were incubated for 24h at 37°C with or without G. lamblia trophozoites and the cell
Supematants were analyzed for NEFAs. Survival and growth of the parasites in those different conditions were determined.

The following Table 1 represents the analysis of non-esterified fatty acids involvement in *Giardia* inhibition. The different components of the *Giardia* culture medium (FCS 10% and/or bile 0.5 g/L), as well as LjLalsn, were analyzed either alone or in combination for NEFA content after 24h of incubation at 37°C. Incubation was performed with or without *G. lamblia* trophozoites (9.6 X 10⁴/ml). Survival and multiplication of *G. lamblia* after 24 h in those different media were determined. Parasite multiplication was expressed as the number of total trophozoites after 24 h of incubation / number of trophozoites at time zero of incubation (i.e. multiplication factor). Trophozoite survival rate after 24h of incubation was expressed as the (number of living cells / total number of cells) x 100. ± SD (triplicate).

Supematants with FCS, LjLalsn or bile alone displayed NEFAs concentrations of 40.9, 36.3 and 4.5 μM, respectively (Table 1).

<table>
<thead>
<tr>
<th>Incubation medium</th>
<th>NEFAs (μM Eq)</th>
<th>Multiplication factor</th>
<th>Survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KM</td>
<td>0</td>
<td>1.1</td>
<td>14.3</td>
</tr>
<tr>
<td>KM + FCS</td>
<td>40.9</td>
<td>3.3</td>
<td>89.8</td>
</tr>
<tr>
<td>KM + bile</td>
<td>4.5</td>
<td>0.7</td>
<td>0</td>
</tr>
<tr>
<td>KM + LjLalsn</td>
<td>36.4</td>
<td>1.2</td>
<td>71.6</td>
</tr>
<tr>
<td>KM + FCS + bile</td>
<td>95.4</td>
<td>2.3</td>
<td>93.8</td>
</tr>
<tr>
<td>KM + FCS + LjLalsn</td>
<td>68.2</td>
<td>2.1</td>
<td>87.5</td>
</tr>
<tr>
<td>KM + bile + LjLalsn</td>
<td>50.0</td>
<td>0.8</td>
<td>0</td>
</tr>
<tr>
<td>KM + FCS + bile + LjLalsn</td>
<td>140.9</td>
<td>0.8</td>
<td>0</td>
</tr>
</tbody>
</table>

The amount of NEFAs was doubled (95.4 μM) by co-incubation of the bile with serum suggesting enzymatic release of NEFAs. However, equal amounts were found at time zero and time 24h of the co-incubation (not shown), indicating that fatty acids were not released in a time-dependent manner. It was hypothesized that the high amount of NEFAs might result from a detergent-like action of the bile on serum lipids, possibly improving accessibility of NEFAs to the NEFA-C kit reagents. The highest amount of NEFAs (140.9 μM) was measured upon co-incubation of FCS with bile and LjLalsn, as could be expected by summing their respective
NEFAs contents. Incubation with *G. lamblia* had no noticeable effect on the NEFA content of the various samples (Data not shown).

Normal growth of *G. lamblia* (multiplication factor: 3.34, Table 1) was observed in the presence of 10% FCS alone. Trophozoites did not survive in KM medium containing only bile, whereas most of them (-70%) were still alive although they did not develop when incubated in KM with LjLal supernatant, most probably due to the low concentration of FCS in LjLal supernatant. Remarkably, trophozoites survival was abolished upon addition of bile to LjLal sn although the same concentration of FCS is present, indicating the presence of inhibitory elements. By comparing NEFAs contents of the different media, it appeared that NEFAs could hardly be responsible for parasite death. Indeed, more NEFAs were found in the KM + FCS + bile or KM + FCS + LjLal sn media (95.4 and 68.2 μM of NEFAs respectively), which allowed parasite survival, than in the KM + bile + LjLal sn medium (50.0 μM of NEFAs) which induced the death of all the parasites. This indicated that the concomitant addition of bile and bacterial supernatant rather than high level of NEFAs is lethal to *Giardia* and is responsible for the killing effect observed in the presence of FCS, bile and LjLal supernatant.

**Example 5: Characterization of LjLal supernatant inhibitory activity**

The LjLal supernatant inhibitory activity is due to ~ 30 kDa molar mass factor(s)

Fractionation experiments indicated that the inhibitory activity in LjLal supernatant was due to molecule(s) bigger than 10 kDa, since fraction >10 showed a high *G. lamblia* inhibitory activity compared to the fraction <10 kDa (Figure 2C). By performing a 30 kDa threshold fractionation, we found that the inhibitory activity concentrated mostly in the >30kDa fraction (inducing 66% of *Giardia* growth inhibition, Figure 2C), however moderate inhibitory effect (~ 40%) was also observed with the <30 kDa fraction, which led us to propose that the molar mass(es) of the active molecule(s) are close to this threshold. In good accordance with this, 50 kDa threshold fractionation of the LjLal sn was unable to segregate the inhibitory activity, i.e. 50% and 48% of *Giardia* growth inhibition were induced by the <50 kDa and >50 kDa fractions, respectively (Figure 2C), indicating that inhibitory protein(s) molar mass is smaller than 50 kDa.

Small compounds are not primarily involved in LjLalsn inhibitory activity

It has been reported that molecule(s) smaller than 1 kDa (Perez *et al.*, 2001) would be involved in the giardiacidal activity of the LjLal supernatant, in contradiction with our findings of a > 30 kDa molecule(s). The possibility that dialysis against GKN buffer as used in Perez's report might somehow inhibit the activity has been checked. Several points were checked. At first,
because the pH of the GKN buffer is 7.4 and the LjLalsn inhibitory activity is inactivated at pH above 7.0 (Figure 2B), pH of the KM medium was checked after supplementation with 10% FCS and 25% GKN. The pH was found to be increased to 6.5, hence not expected to inactivate LjLal supernatant (Figure 2B). Second, to assess whether small component(s) might be involved in the inhibitory effect, the bacterial supernatant was dialyzed using a 3.5 kDa molecular weight cut-off membrane against both KM 10% FCS and GKN buffer. As can be seen in the following Table 2, parasite killing activity of the LjLal supernatant in the presence of bile was fully recovered after dialysis, whatever the dialysis solution. Table 2 represents dialysis through low MW cutoff membrane does not inactivate inhibitory activity of LjLal supernatant (LjLalsn). KM-FCS medium, bile (0.5 g/L) and LjLalsn, either alone or in combination, were dialyzed against GKN buffer or KM-FCS, and then tested for G. lamblia trophozoites growth. Values are mean of two independent experiments performed in duplicate.

<table>
<thead>
<tr>
<th>Multiplication factor</th>
<th>KM + FCS</th>
<th>KM + FCS + LjLalsn</th>
<th>KM + FCS + LjLalsn dialysed against KM-FCS</th>
<th>KM + FCS + LjLalsn dialysed against GKN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival rate (%)</td>
<td>93.7</td>
<td>92.3</td>
<td>88.3</td>
<td>90.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>89.3</strong></td>
</tr>
</tbody>
</table>

This indicates on one side that no element crucial to activity is lost upon dialysis and on the other side that the GKN buffer is not inhibitory to the LjLal supernatant activity. Also, it can be
noticed from Table 2 that addition of 25% GKN buffer to KM-FCS does not affect parasite survival but slows down its development (multiplication rate of 2.60 in the presence of GKN versus 3.82 in the absence of GKN).

**Example 6: Impact of LjLal supernatant on bile composition**

Since concomitant addition of bile and LjLalsn to the culture medium leads to inhibition of *G. lamblia* growth, we assessed whether bile composition might be modified by LjLal supernatant. Bile composition after 24h of incubation with LjLalsn was investigated by mass spectrometry (Figures 3A-B). Impacted molecules were identified by their MS/MS fragmentation pattern. The bile composition was modified in favor of non-conjugated bile salts such as cholate and desoxycholate, which were the major bile salts in the absence of LjLal supernatant (Figure 4). This was associated with a decrease in the levels of conjugated bile salts which were not observed in the presence of heat-treated bacterial supernatant (Figure 3C).

**Example 7: Impact of deconjugated bile salts on *G. lamblia* trophozoites growth**

The inhibitory effects toward *G. lamblia* growth of pure bile salts (cholate, desoxycholate and chenodesoxycholate) conjugated to glycine or taurine, or their deconjugated counterparts were investigated in the presence or the absence of LjLal supernatant (Table 3, Figure 5). In the absence of LjLalsn, glycyl- or tauryl-conjugated salts as well as deconjugated cholate showed no apparent toxicity at the concentrations tested (IC$_{50}$ values > 500 µM). In contrast, the deconjugated bile salts DC and CDC exhibited inhibitory effects on trophozoites growth with IC$_{50}$ values of 132 µM (DC) and 147 µM (CDC) respectively. Interestingly, in the presence of LjLal supernatant, the conjugated bile salts IC$_{50}$ values fell to a range of values similar to those measured for their pure deconjugated counterparts, i.e. 104 µM (GDC), 79 µM (TDC), 110 µM (GCDC) and 115 µM (TCDC) (Table 3 and Figure 5).

The following table 3 shows conjugated bile salts in association with LjLal supernatant (LjLalsn) as well as deconjugated bile salts prevent the growth of *G. lamblia*. Various concentrations of taurine- and glycine-conjugated and unconjugated C, DC and CDC bile salts were tested for *G. lamblia* trophozoites growth inhibition in KM-FCS in the presence or absence of LjLalsn (bacterial spent culture medium). IC50 values were determined from drug-response curves and expressed as mean +/- SD of at least three independent experiments.
These results suggested that a deconjugating process mediated by LjLalsn component(s) and producing deconjugated bile salts might be responsible for the inhibitory effect of the association of bile and LjLalsn. Such hypothesis is in line with the previous observation that fusidic acid, an antibiotic with a bile salt-like chemical structure is toxic to Giardia (see Table 3, IC50 value = 26 µM) unless conjugated to taurine or glycine (Farthing et al., 1986).

Example 8: Potential involvement of L. Johnsonii Lai bile-salt hydrolase(s) in bile-mediated Giardia inhibition, and co-elution of BSH-like activity and Giardia inhibitory activity in size fractionation chromatography of LjLal supernatant

It is known that bile salt deconjugating process is mediated by 3-alpha, 7-alpha, 12-alpha-trihydroxy-5-beta-cholan-24-oylglycine / taurine amidohydrolases (EC 3.5.1.24), also named choloylglycine / taurine hydrolases or conjugated bile acid hydrolases (CBAH) or bile salt hydrolases (BSH). These enzymes act on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides, releasing glycine and taurine from conjugated bile salts. In L. johnsonii genome, three genes encoding BSH-like enzymes have been predicted (LJ0056 (BSH-56), LJ1147 (BSH-47) and LJ1412 (BSH-12) genes). They are also predicted as secreted proteins by SecretomeP, with theoretical full sizes of 34.9 kDa, 36.3 kDa and 36.6 kDa and secreted sizes of 29.8 kDa, 31.0 kDa and 31.3 kDa (data not shown).
To test the hypothesis of bacterial BSH(s) involvement in *G. lamblia* growth inhibitory activity by LjLalsn, the bacterial supernatant was fractionated by gel filtration chromatography on Sephacryl S300 column 16/100, and eluted fractions were assayed for parasite inhibition and bile salt deconjugating activity.

A typical elution profile is shown in Figure 5A. Twelve eluted fractions (Figure 5A) were tested for *G. lamblia* growth inhibition (Figure 5C) and the most active ones were further tested for BSH-like activity (Figure 5B). Greatest inhibitory activity was recovered from fractions containing proteins with molecular weight between 13.7 kDa and 67 kDa (Figure 5A). Those fractions exhibited BSH-like activity (Figure 5C), as measured by the release of glycine from GDCA. In our experimental conditions, 1 unit of the commercial *Clostridium perfringens* BSH induced the release of 0.76 mM glycine from 2.5 mM GDC within 24 hours. Concomitant elution of inhibitory and BSH activities within similar molecular weight range was observed with LjLal supernatants from different culture batches. Our attempts to further purify elements responsible for inhibitory activity and/or BSH-like activity by combining steps of ion-exchange chromatography, hydrophobic interaction chromatography and chromatofocusing were unsuccessful, with a rapid loss of the activities.

**Example 9: Deconjugation of tauryl- and glycyl-DC and -CDC by Clostridium perfringens**

**BSH is toxic to G. lamblia**

To assess capability of BSH enzymes to promote bile-mediated anti-*Giardia* effect, BSH from the bacteria *C. perfringens* was tested for *G. lamblia* growth inhibition in the presence of bile or pure conjugated bile salts. As noted above (Table 3), the glycine or taurine conjugated bile salts, TDC, TCDC, GDC and GCDC have no inhibitory activity on *G. lamblia* growth in KM-FCS culture medium. In contrast, the addition of 2 units of *C. perfringens* BSH to the culture in the presence of those bile salts led to a remarkable parasite growth inhibition within the 24 h of the assay, with inhibition ranges of 95 to 100%, depending upon the conjugated bile salt tested (Figure 6). Heat inactivation of bacterial BSH (100°C, 5 min) before its addition to the parasite culture led to a dramatic fall of its anti-*Giardia* activity (less than 10% growth inhibition depending upon the conjugated bile salts tested, Figure 6) indicating that BSH inhibitory activity depends on its enzymatic activity.

**Example 10: Mass spectrometric identification of two BSH-like enzymes in the LjLalsn.**

It was then searched whether BSH-like enzymes annotated from *L. johnsonii* Lai genome, and predicted by SecretomeP to be secreted, are indeed released in the extracellular medium. High-
resolution mass spectrometry-based proteomic analysis of the LjLal extracellular proteins was performed. 3 \( \mu \)g of proteins of LjLal supematants from two independent culture replicates allowed identification of over a hundred of secreted protein groups (data not shown). Amongst them, two of the three predicted BSH were clearly identified in both replicates: LJ1412 (gi|41583570) and LJ1 147 (gi|41583360). The following Table 4 shows the identification of two conjugated bile salt hydrolases of Lactobacillus johnsonii NCC533 by MS/MS peptide fragmentation using MASCOT stringent search.

<table>
<thead>
<tr>
<th>Accession number</th>
<th>Score</th>
<th>Cov. (%)</th>
<th>Unique peptides</th>
<th>Total peptides</th>
<th>PSMs</th>
<th>Peptide ion sequence (^a) (with at least one peptide ion score (&gt;50))</th>
<th>Charge</th>
<th>Peptide ion (m/z)</th>
<th>Theor. Mass (kDa)</th>
<th>Theor. pI (^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>experimental replicate 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gi</td>
<td>41583570</td>
<td>162</td>
<td>12.58</td>
<td>2</td>
<td>5</td>
<td>NLANYSNHAPQPK AHSQGNNELSSVTNYFHILHSVEQPK</td>
<td>2 4</td>
<td>750.9</td>
<td>759.1</td>
<td>36.6</td>
</tr>
<tr>
<td>gi</td>
<td>41583360</td>
<td>39</td>
<td>12.92</td>
<td>3</td>
<td>3</td>
<td>GLGIAAGLNFTGPQK DLPYTTLHMLMGDK NTLVPNADINLYSR</td>
<td>2 2</td>
<td>813.4</td>
<td>795.4</td>
<td>36.3</td>
</tr>
<tr>
<td>experimental replicate 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gi</td>
<td>41583570</td>
<td>83</td>
<td>12.58</td>
<td>2</td>
<td>3</td>
<td>NLANYSNHAPQPK AHSQGNNELSSVTNYFHILHSVEQPK</td>
<td>2 4</td>
<td>750.9</td>
<td>759.1</td>
<td>36.6</td>
</tr>
<tr>
<td>gi</td>
<td>41583360</td>
<td>77</td>
<td>8.62</td>
<td>2</td>
<td>3</td>
<td>GLGIAAGLNFTGPQK NTLVPNADINLYSR</td>
<td>2 2</td>
<td>651.4</td>
<td>795.4</td>
<td>36.3</td>
</tr>
</tbody>
</table>

\( ^a \) Accession number in the NCBI protein database. All accession numbers refer to sequences from Lactobacillus johnsonii NCC 533; 
\( ^b \) Probability-based Mowse score of MASCOT software that evaluates if the peptides subjected to search are the same as those found in the database originated by in silico digestion of a known protein; 
\( ^c \) Coverage is the percentage of predicted protein sequence covered by matched peptides via MASCOT; 
\( ^d \) Peptide sequences identified via MASCOT following the experimental peptide masses after parental ion fragmentation. It was required that at least one spectrum should be matched with score of 50 or better to considered the hit.

Example 11: Measurement of G. lamblia inhibition by flow cytometry

The inhibitory effect of L. johnsonnii on G. lamblia was measured by flow cytometry, as shown in Figures 7A to 7E. Propidium iodide, an intercalating agent fluorescing when excited at 540nm, was used to evaluate Giardia cell viability in order to confirm Hemocytometer results. These results showed that, tested separately, neither LjLal sn nor bovine bile (0.6g/L) have cell
lisis activity. However, in presence of both Ljlalsn and bovine there is a fluorescence shift (Figure 7E) evincing that bile has a cytotoxic effet on Giardia trophozoites (Figure 7D :Figure 7E). Flow cytometry allowed us to analyse a higher amount of cells and may be used routinely as a measurement method of G lamblia inhibition. Moreover, this technique has been used for other lactobacilli supernatant (data not shown).

Example 12: Identification of anti-Giardiasis lactobacilli strains
The inhibitory effect on G lamblia growth of different lactobacilli strains was screened (cf. table 5). Bacterial supernatant was co-incubated for 24h at 37°C with Giardia trophozoite cultures (triplicates), with or without bovine bile (0.6 g/L). Different species of lactobacilli were identified as potent inhibitors of Giardia lamblia growth, as Lactobacillus johnsonii, Lactobacillus gasser, Lactobacillus acidophilus, Lactobacillus reuteri. 14 lactobacilli strains showed significant inhibitory effects (ANOVA statistic tests) in presence of bile (Figure 8) None of the supernatant had an inhibitory effect without bovine bile, confirming that the giardiacidal effect is bile dependent. Table 5 indicates the corresponding internal and official references of the bacterial strains, and bibliographic references.
Example 13: Heterologous expression of *LjLal* BSH in *E. coli*

To study the properties of the *LjLal* BSHs, we cloned the BSH genes into a pStaby vector (StabyExpress, Delphigenetics) in order to purify BSHs using His-Tag system. *E.coli*
expressions cells (*E. coli* SE, Delphigenetics) were then transformed. The recombinant BSH-47 protein was produced in *E. coli* SE cells and purified using a His-Tag system (Sephadex Ni-NTA column, GE Healthcare). The activity of recombinant BSH-47 was tested using taurodeoxycholic (0.3%) and glycodeoxycholic (0.3%) LB agar (Chae et al 2013). After 48h of incubation at 37°C, we observed that the recombinant BSH-47 is taurospecific (Figure 9).

Furthermore, the effect of recombinant *LjLal* BSH-47 has been studied on *Giardia* trophozoites cultures, in the presence or not of bovine bile (0.06 g/L). The results show that recombinant BSH-47 (0.96 U, with "U" designing enzymatic units) exhibits an inhibiting effect, the level of this inhibiting effect is equivalent to the inhibiting effect of *C. perfringens* BSH (1U) (Figure 10).

**Example 14: Characterization of the inhibitory activity of *LjLal* BSH-47 and BSH-56 in vitro**

The effects of recombinant *LjLal* BSH-47 and BSH-56 were studied on cultures of *G. lamblia* trophozoites in either presence or absence of bovine bile (0.06 g/L). Recombinant BSH-56 was produced according to the process described for the production of BSH-47, such as described in Example 13. Several BSH concentration were tested ranging from 0,000 µg/ml to 10µg/ml. Interestingly, both BSH-47 (Figure 11A) and BSH-56 (Figure 11B) exhibit strong inhibitory effects. These results are in agreement with those obtained with commercial *C. perfringens* BSH (Example 8) (Figure 10). As expected, no inhibitory effect was observed without bovine bile.

**Specific activities:**

Previous experiments allowed us to determine the substrate specificity of newly purified BSH-47 and BSH-56 and their specific activities had been determined. BSH-47 is able to deconjugate taurospecific bile salts while BSH-56 is able to deconjugate both taurospecific and glycospecific bile salts.

**Table 6**

<table>
<thead>
<tr>
<th></th>
<th>Specific activity (µmol of glycine /5min at 37°C / mg of protein)</th>
<th>Specific activity (µmol of taurine /5min at 37°C / mg of protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>C. perfringens</em></td>
<td>0,690</td>
<td>0,150</td>
</tr>
<tr>
<td>BSH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BSH-47</td>
<td>0,066</td>
<td>0,717</td>
</tr>
<tr>
<td>BSH-56</td>
<td>0,536</td>
<td>2,604</td>
</tr>
</tbody>
</table>
Example 15: *In vivo* effect of *L. gasseri* CNCM 1-4884 against *G. lamblia*

*L. johnsonii* Lai and *L. gasseri* CNCM 1-4884 strains (*L. gasseri* CNCM 1-4884 is also designated as *L. gasseri* ATCC29601 in Figure 8 and in Table 5) were daily administered by intragastric gavage (5x10⁸ CFU) to neonatal mice from day 5 to day 15 (day of sacrifice). Mice were challenged with trophozoites at day 10 by intragastric gavage (1x10⁵ trophozoites) and then were sacrificed at day 15. Preliminary experiments allow us to determine that there is a peak in the Giardia infection rate 5 days postinoculation (data not shown). The presence of living trophozoites in the small intestine is a marker of Giardia infection. Mice were divided into three groups with a minimum of 8 animals per group. We observed a significant reduction (p<0.05) in the parasite load in the small intestine in groups treated with *L. gasseri* CNCM 1-4884 compared to control animals administered with PBS (Figure 12A). Interestingly, *L. gasseri* CNCM 1-4884 was more efficient in reducing the number of trophozoites than *L. johnsonii* Lai. In agreement with these observations, the counting of cysts in the large intestine showed a significant reduction (p<0.05) in groups treated with *L. gasseri* CNCM 1-4884 compared to controls, whereas no significant reduction was observed in the group treated with *L. johnsonii* Lai (Figure 12B).

Example 16: *In vivo* effect of BSH-47 against *G. lamblia*

Solutions of recombinant BSH-47 solutions (4µg/ml, 10µg/ml and 100µg/ml diluted in NaHC03 16.4%) were thawed and daily administered by intragastric gavage to neonatal mice (dose were respectively 0.05µg, 0.4µg and 5µg per mice) from day 10 to day 15 (day of sacrifice). Control animals received PBS instead of BSH. All groups treated with BSH-47 showed a reduction in trophozoites load in the small intestine compared with the control (Figure 13). However, only the group treated with 100µg/ml of BSH-47 displayed significant reduction in the parasite load.
BIBLIOGRAPHIC REFERENCES


<table>
<thead>
<tr>
<th>0-1</th>
<th>Form PCT/RO/134</th>
<th>Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1-1</td>
<td>Prepared Using</td>
<td>PCT Online Filing Version 3.5.000.244e MT/FOP 20141031/0.20.5.20</td>
</tr>
<tr>
<td>0-2</td>
<td>International Application No.</td>
<td></td>
</tr>
<tr>
<td>0-3</td>
<td>Applicant's or agent's file reference</td>
<td>368241D33847</td>
</tr>
</tbody>
</table>

1. The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:
   1-1 page 9
   1-2 line 3-4

2. The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:
   2-1 page 8
   2-2 line 25-26

### Identification of deposit

<table>
<thead>
<tr>
<th>1-3-1</th>
<th>Name of depositary institution</th>
<th>CNCM Collection nationale de cultures de microorganismes (CNCM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3-2</td>
<td>Address of depositary institution</td>
<td>Institut Pasteur, 28, Rue du Docteur Roux, 75724 Paris Cédex 15, France</td>
</tr>
<tr>
<td>1-3-3</td>
<td>Date of deposit</td>
<td>07 August 2014 (07.08.2014)</td>
</tr>
<tr>
<td>1-3-4</td>
<td>Accession Number</td>
<td>CNCM I-4884</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2-3-1</th>
<th>Name of depositary institution</th>
<th>CNCM Collection nationale de cultures de microorganismes (CNCM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-3-2</td>
<td>Address of depositary institution</td>
<td>Institut Pasteur, 28, Rue du Docteur Roux, 75724 Paris Cédex 15, France</td>
</tr>
<tr>
<td>2-3-3</td>
<td>Date of deposit</td>
<td>07 August 2014 (07.08.2014)</td>
</tr>
<tr>
<td>2-3-4</td>
<td>Accession Number</td>
<td>CNCM I-4885</td>
</tr>
</tbody>
</table>

### Designated States for Which Indications are Made

| 1-5 | Designated States for Which Indications are Made | All designations |

| 2-5 | Designated States for Which Indications are Made | All designations |

**FOR RECEIVING OFFICE USE ONLY**

<table>
<thead>
<tr>
<th>0-4</th>
<th>This form was received with the international application: (yes or no)</th>
<th>YES</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4-1</td>
<td>Authorized officer</td>
<td>Wilson, Patrick</td>
</tr>
</tbody>
</table>

**FOR INTERNATIONAL BUREAU USE ONLY**

<table>
<thead>
<tr>
<th>0-5</th>
<th>This form was received by the international Bureau on:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0-5-1</td>
<td>Authorized officer</td>
<td></td>
</tr>
</tbody>
</table>
CLAIMS

1. Composition exhibiting a bile-salt hydrolase activity for use for the treatment or the prevention of giardiasis, wherein said composition is chosen in the group consisting of:
   - a composition comprising at least one bile-salt hydrolase (BSH) enzyme,
   - a composition comprising a lactic acid bacterium able to secrete at least one BSH enzyme, with the exception of Lactobacillus johnsonii Lai, Lactobacillus acidophilus, Bifidobacterium bifidum and Bifidobacterium infantis.
   - a composition comprising a recombinant host cell able to secrete at least one heterologous BSH enzyme, and
   - a combination thereof,
   wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.

2. The composition for use according to claim 1, wherein said bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.

3. The composition for use according to claim 2, wherein said BSH enzyme is chosen among BSH from prokaryotes, and preferably among BSH from lactic acid bacteria.

4. The composition for use according to any one of claims 1 to 3, wherein said BSH enzyme comprises an amino acid sequence having at least 80% identity with, or is a natural variant of, an amino acid sequence chosen in the group consisting of:
   - Lactobacillus johnsonii Lai BSH-12 (SEQ ID No1), Lactobacillus johnsonii Lai BSH-47 (SEQ ID No2), Lactobacillus johnsonii Lai BSH-56 (SEQ ID No3),
   - Lactobacillus gasseri BSH-A (SEQ ID No4), Lactobacillus gasseri BSH-B (SEQ ID No5),
   - Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No6),
   - Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No7), and
   - Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No8).
5. The composition for use according to any one of claims 1 to 4, said composition comprising a lactic acid bacterium able to secrete a BSH, wherein said bacterium is chosen among:
   - *Lactobacillus*, with the exception of *Lactobacillus johnsonii* Lai and of *Lactobacillus acidophilus*,
   - *Bifidobacterium*, with the exception of *Bifidobacterium bifidum* and *Bifidobacterium infantis*.

6. The composition for use according to claim 5, wherein said lactic acid bacterium is a *Lactobacillus* chosen in the group consisting of:
   - *Lactobacillus johnsonii*, with the exception of *Lactobacillus johnsonii* Lai,
   - *Lactobacillus gasseri*,
   - *Lactobacillus acidophilus*, with the exception of *Lactobacillus acidophilus LalO*, and
   - *Lactobacillus reuteri*.

7. The composition for use according to claim 5 or 6, wherein said *Lactobacillus* is chosen in the group consisting of the bacterial strains referenced as:
   - *Lactobacillus johnsonii*: filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4885, on August 7, 2014

8. A host cell for use for the treatment or the prevention of giardiasis, said host cell comprising an heterologous nucleic acid comprising at least one of the following nucleotide sequences:
   - nucleotide sequence encoding for *L. johnsonii Lai BSH-12* (SEQ ID NO9), or a natural variant thereof,
   - nucleotide sequence encoding for *L. johnsonii Lai BSH-47* (SEQ ID NO10), or a natural variant thereof,
   - nucleotide sequence encoding for *L. johnsonii Lai BSH-56* (SEQ ID NO11), or a natural variant thereof,

wherein said host cell is able to secrete a BSH enzyme.
9. A host cell according to claim 8, wherein said host cell is a lactic acid bacterium.

10. Composition for use in the treatment or the prevention of giardiasis according to any one of claims 1 to 7, for the treatment or the prevention of giardiasis in human beings.

11. Composition for use in the treatment or the prevention of giardiasis according to any one of claims 1 to 7, for the treatment or the prevention of giardiasis in animals, and in particular for pigs and cows.

12. Pharmaceutical composition comprising, as an active principle, a composition exhibiting a bile-salt hydrolase activity according to any one of claims 1 to 7, and a pharmaceutically acceptable carrier.

13. Food composition or dietary supplement comprising, as an active principle, a composition exhibiting a bile-salt hydrolase activity according to any one of claims 1 to 7, and a carrier.

14. Process for the preparation of a pharmaceutical composition according to claim 12 or for the preparation of a food composition or dietary supplement according to claim 13, said process comprising a step of contacting a carrier and at least one of the following elements, or a combination thereof:
   - A bile-salt hydrolase (BSH) enzyme,
   - A bacterium able to secrete at least one BSH, with the exception of the bacterial strains *Lactobacillus johnsonii Lai* (public reference NCC533, CNCM 1-1225), *Lactobacillus acidophilus LalO* (NCC90, CNCM 1-2332), *Bifidobacterium bifidum* (NCC189, CNCM 1-2333) and *Bifidobacterium infantis* (NCC200, CNCM 1-2334),
   - A recombinant host cell able to secrete at least one BSH.
Figure 2A

Figure 2B
Figure 3B

Figure 3C
Figure 5C

Figure 6
Figure 7A

a- KM (contrôle)

Figure 7B

b- KM + bile

Figure 7C

c- KM + Sup LjLA1
Figure 7D

**d** - KM + Sup *LjLA1* + bile

Figure 8

% living parasites

---

KM

*L. gasseri* ATCC33223
*L. johnsonii* CIP103614
*L. johnsonii* ATCC11506
*L. johnsonii* CIP103654
*L. johnsonii* ATCC700396
*L. johnsonii* CNCM I-4885
*L. gasseri* CIP103782
*L. johnsonii* ATCC11413
*L. johnsonii* LMG11469
*L. johnsonii* CIP103786
*L. johnsonii* NCC533 (La1)
*L. gasseri* ATCC28801

*** ρ < 0.0001
Figure 9
Effect of BSH47 from LjLa1 on *Giardia* cultures

Living parasites (cells/ml)

- KM
- KM + bile
- BSH C. perfringens 1 u
- BSH C. perfringens 1 u + bile
- BSH 47 0.96 u
- BSH 47 0.96 u + bile

Figure 10
Figure 13
### INTERNATIONAL SEARCH REPORT

**International application No**

PCT/EP2015/068334

**A. CLASSIFICATION OF SUBJECT MATTER**

INV. A61K38/00 A23L1/30 A61K38/16 A61K38/46 A61K35/74 A61P33/02 C07K14/335

**ADD.**

According to International Patent Classification (IPC) into both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K A23L C12N A61P C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 6 905 679 BI (SCHI FFRIN EDUARDO [CH] ET AL) 14 June 2005 (2005-06-14) cited in the application on column 9, line 53 - line 56 column 1, paragraph 1</td>
<td>1-14</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

A: document defining the general state of the art which is not considered to be of particular relevance

E: earlier application or patent but published on or after the international filing date

L: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O: document referring to an oral disclosure, use, exhibition or other means

P: document published prior to the international filing date but later than the priority date claimed

T: later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X: document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y: document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A: document member of the same patent family

### Date of the actual completion of the international search

7 October 2015

### Date of mailing of the international search report

14/10/2015

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2

NL - 2280 HV RIjswijk

Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer

Zel lner, Eveli ne
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>wo 03/084989 A2 (NESTLE SA [CH]; PRIDMORE RAYMOND DAVID [CH]; MOLLET BEAT [CH]; ARIGONI) 16 October 2003 (2003-10-16) page 3, paragraph 2; example 6 page 6 2 page 13 - paragraph 2; table 1 -----</td>
<td>1-14</td>
</tr>
<tr>
<td>Y</td>
<td>wo 2004/076657 A2 (UNIV MCGILL [CA]; PRAKASH SATYA [CA]; JONES MITCHELL LAWRENCE [CA]) 10 September 2004 (2004-09-10) page 14; figure 9 page 17, paragraph 2; claims 1, 18, 19; example 6 -----</td>
<td>1-14</td>
</tr>
<tr>
<td>Y</td>
<td>KR 2009 0126757 A (SUN BIO CO LTD [KR]; IND ACADEMIC COOP [KR]) 9 December 2009 (2009-12-09) claims 1-12; figure 4 -----</td>
<td>1-14</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>US 6905679 B1</td>
<td>14-06-2005</td>
<td>AP 1563 A 02-02-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AR 026248 A 05-02-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 290393 T 15-03-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1025001 A 08-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR 0015102 A 16-07-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2388952 A 03-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1382056 A 27-11-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CO 5280049 A 30-05-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60018591 D1 14-04-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 60018591 T2 13-04-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1227827 T3 11-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1227827 A1 07-08-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2239622 T3 01-10-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX PA02004115 A 17-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OA 12074 A 04-05-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PE 06762001 A1 11-07-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1227827 E 29-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6905679 B1 14-06-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2005186191 A1 25-08-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0130365 A1 03-05-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 200203008 A 23-09-2003</td>
</tr>
<tr>
<td>WO 03084989 A2</td>
<td>16-10-2003</td>
<td>AT 403718 T 15-08-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2003223971 A1 20-10-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2482138 A1 16-10-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1659280 A 24-08-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1497422 T3 15-12-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1497422 A2 19-01-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1816196 A1 08-08-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2311700 T3 16-02-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2006506042 A 23-02-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008044820 A1 21-02-2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009098053 A1 16-04-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03084989 A2 16-10-2003</td>
</tr>
<tr>
<td>WO 2004076657 A2</td>
<td>10-09-2004</td>
<td>CA 2517245 A1 10-09-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1639108 A2 29-03-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010074933 A1 25-03-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2004076657 A2 10-09-2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2010028945 A1 04-02-2010</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2005086794 A2 22-09-2005</td>
</tr>
<tr>
<td>KR 20090126757 A</td>
<td>09-12-2009</td>
<td>NONE</td>
</tr>
</tbody>
</table>